Public health groups warn that projects not considered innovative, such as smoking-cessation campaigns to prevent cancer and cardiovascular disease, would struggle to secure funds designated to boost industry competitiveness in the region.<\/p>\n
In response, the health committee is pushing to boost health funding and dedicate it solely to health projects. However, without the committee leading on the file, health MEPs have limited influence over their demands.<\/p>\n
Radan Kanev, MEP for the European People\u2019s Party, is the author of the committee’s draft opinion on health funding in the proposed competitiveness fund. \u201cI hope these figures will not be frightening to our colleagues,\u201d Kanev told POLITICO, referring to MEPs on other committees as well as national governments. \u201cIt is really needed \u2026 to show the benefits of scale for European health policy,\u201d he said.<\/p>\n
His report asks for a carve-out of \u20ac15.55 billion for health (from the \u20ac20.4 billion health-agriculture-bioeconomy pot of the competitiveness fund). From this, \u20ac5.5 billion would support industrial competitiveness in areas including pharma and medical devices, he said.<\/p>\n
The other \u20ac10.05 billion would be reserved for health policies covered by the European Commission\u2019s current health budget, EU4Health \u2014 around double its original pot.<\/p>\n
The committee wants \u20ac2.5 billion from this pot to fund Europe\u2019s Beating Cancer Plan and \u20ac400 million for HERA Invest, a scheme that supports medical countermeasures against pandemic threats and antimicrobial resistance.<\/p>\n","protected":false},"excerpt":{"rendered":"Public health groups warn that projects not considered innovative, such as smoking-cessation campaigns to prevent cancer and cardiovascular…\n","protected":false},"author":2,"featured_media":21788,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2387],"tags":[15527,83,367,2202,10064,258,15528,4619,11116,9224,15529],"class_list":["post-21787","post","type-post","status-publish","format-standard","has-post-thumbnail","category-european-parliament","tag-christian-ehler","tag-competitiveness","tag-defense","tag-digital-health","tag-eu-budget","tag-european-parliament","tag-frank-vandenbroucke","tag-medicines","tag-pharma","tag-public-health","tag-radan-kanev"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts\/21787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/comments?post=21787"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts\/21787\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/media\/21788"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/media?parent=21787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/categories?post=21787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/tags?post=21787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}